Home > Insider Trading > Filing (0001209191-21-035364)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1699382	Pmv Pharmaceuticals Inc.	PMVP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1341642	Henry David Mack	C/O Pmv Pharmaceuticals, Inc. 8 Clarke Drive, Suite 3 Cranbury NJ 08512	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-05-20	7,793	$0.53	10,263	No	4	M	Direct
Common Stock	Disposition	2021-05-20	7,793	$35.60	2,470	No	4	S	Direct
Common Stock	Acquisiton	2021-05-21	6,207	$0.53	8,677	No	4	M	Direct
Common Stock	Disposition	2021-05-21	6,207	$35.71	2,470	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-05-20	7,793	$0.00	7,793	$0.53
Common Stock	Stock Option (right to buy)	Disposition	2021-05-21	6,207	$0.00	6,207	$0.53

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
492,867		2025-05-11	No	4	M	Direct
485,074		2025-05-11	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	227,915	Indirect	See footnote
Common Stock	56,978	Indirect	See footnote

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $35.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $35.99, inclusive.
The shares are held of record by The Mack-Mulligan Revocable Trust, for which the Reporting Person serves as co-trustee.
The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust, for which the Reporting Person serves as co-trustee.
The shares subject to the option are fully vested and immediately exercisable.